Aeon Biopharma Capital Raise of $6.2M
AEON Biopharma entered into a warrant amendment to reduce the exercise price of its outstanding two-year milestone warrants from $0.3221 to $0.20 per share. Certain holders have agreed to exercise their warrants at this reduced price, which is expected to generate approximately $6.2 million in gross proceeds for the company. The warrants were triggered for accelerated expiration following FDA feedback on the company's ABP-450 biosimilar pathway and will expire on November 16, 2026.
- Value
- $6.2M